Erythropoietin for stroke treatment: Dead or alive?

Critical Care

Volumn 15, Issue 2, 2011, Pages

  Minnerup, Jens ^a   Wersching, Heike ^b   Schäbitz, Wolf Rüdiger ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c EVANGELISCHES KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ANTIANEMIC AGENT;

BRAIN INFARCTION SIZE; CELL STIMULATION; DRUG EFFICACY; ENDOTHELIAL PROGENITOR CELL; NEUROLOGICAL COMPLICATION; NOTE; PRIORITY JOURNAL; RECURRENCE RISK; STROKE; TREATMENT OUTCOME; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; METABOLISM; STEM CELL;

ENDOTHELIAL CELLS; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; STEM CELLS; STROKE;

EID: 79956049901     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10057     Document Type: Note

References (16)

1. Yip HK, Tsai TH, Lin HS, Chen SF, Sun CK, Leu S, Yuen CM, Tan TY, Lan MY, Liou CW, Lu CH, Chang WN. Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke. Crit Care 2011, 15:R40. 10.1186/cc10002, 21269484.
2. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005, 111:2981-2987. 10.1161/CIRCULATIONAHA.104.504340, 15927972.
3. Bogoslovsky T, Chaudhry A, Latour L, Maric D, Luby M, Spatz M, Frank J, Warach S. Endothelial progenitor cells correlate with lesion volume and growth in acute stroke. Neurology 2010, 75:2059-2062. 10.1212/WNL.0b013e318200d741, 21135380.
4. Sobrino T, Hurtado O, Moro MA, Rodríguez-Yáñez M, Castellanos M, Brea D, Moldes O, Blanco M, Arenillas JF, Leira R, Dávalos A, Lizasoain I, Castillo J. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke 2007, 38:2759-2764. 10.1161/STROKEAHA.107.484386, 17761925.
5. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. Erythropoietin regulates endothelial progenitor cells. Blood 2004, 103:921-926. 10.1182/blood-2003-04-1284, 14525788.
6. Minnerup J, Heidrich J, Rogalewski A, Schabitz WR, Wellmann J. The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 2009, 40:3113-3120. 10.1161/STROKEAHA.109.555789, 19542052.
7. Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, Liu JS, Youssef AA, Chang HW. Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke 2008, 39:69-74. 10.1161/STROKEAHA.107.489401, 18063830.
8. Zhang ZG, Zhang L, Jiang Q, Chopp M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res 2002, 90:284-288. 10.1161/hh0302.104460, 11861416.
9. Fan Y, Shen F, Frenzel T, Zhu W, Ye J, Liu J, Chen Y, Su H, Young WL, Yang GY. Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Ann Neurol 2010, 67:488-497. 10.1002/ana.21919, 3026588, 20437584.
10. Ohta T, Kikuta K, Imamura H, Takagi Y, Nishimura M, Arakawa Y, Hashimoto N, Nozaki K. Administration of ex vivo-expanded bone marrow-derived endothelial progenitor cells attenuates focal cerebral ischemia-reperfusion injury in rats. Neurosurgery 2006, 59:679-686. 10.1227/01.NEU.0000229058.08706.88, 16955050.
11. Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, Tsukamoto Y, Iso H, Fujimori Y, Stern DM, Naritomi H, Matsuyama T. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004, 114:330-338. 484977, 15286799.
12. Minnerup J, Schabitz WR. Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics 2009, 6:43-52. 10.1016/j.nurt.2008.10.032, 19110198.
13. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jähnig P, Herrmann M, Knauth M, Bähr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C, . EPO Stroke Trial Group Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:e647-e656. 10.1161/STROKEAHA.109.564872, 19834012, EPO Stroke Trial Group.
14. ISRCTN: Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischaemic stroke. , http://www.controlled-trials.com/ISRCTN71371114/
15. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, . TREAT Investigators A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032. 10.1056/NEJMoa0907845, 19880844, TREAT Investigators.
16. Powell TM, Paul JD, Hill JM, Thompson M, Benjamin M, Rodrigo M, McCoy JP, Read EJ, Khuu HM, Leitman SF, Finkel T, Cannon RO. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2005, 25:296-301. 10.1161/01.ATV.0000151690.43777.e4, 15569821.